is not liver cancer. In a second test proved to be the combination of erlotinib and bevacizumab anti-VEGF monoclonal-antique Body, to be feasible, although toxic assets. The aim of this study was the proportion of HCC patients treated with such a combination were alive and determine progression-free at 16 weeks. The choice of this date was a unique way. On the analysis of several NVP-TAE684 previous studies of various chemotherapeutic agents, which have a median PFS of 16 weeks showed This election is the time, not surprisingly, has been criticized by many. Enclosed by the 40 patients who were 12 and 26 stage B and C each BCLC classification, w While only 11 were previously treated with transcatheter arterial chemoembolization. Further evidence that this population is not really repr Sentative of the vast majority of HCC patients that we could see every day only 27 of them had concomitant cirrhosis and only 10 and 6 patients were positive for hepatitis C virus and hepatitis B .
PFS16 median was 62.5, the objective response rate was 25, w While overall survival was 68 weeks. On CUDC-101 the other hand, the toxicity of t is an important issue, with events of grade 3 or 4 adverse events several, such as fatigue, high blood pressure, gastrointestinal bleeding, diarrhea, increase in transaminases and wound infection complications healing. Overall, although this study has been criticized, probably with some reason, he has clearly indicated that the combination of erlotinib plus bevacizumab a more thorough assessment of the case series gr He and Selected earned less Hlten. Gefitinib Gefitinib seemed HCC development in experimental models to prevent. However phase Study of 31 patients showed no significant therapeutic benefit, with a median survival time of 6.5 months, on average, only 2.8 months PFS, no objective response, and only one instance of disease stabilization.
Therefore, unlike his twin, erlotinib, EGFR inhibitor, which seems inappropriate in other clinical trials for HCC, although the reasons for this lack of efficacy are quite heavy. Although lapatinib amplification and overexpression of HER2 new EGFR mutations very rare events in HCC, lapatinib, a dual inhibitor of EGFR and HER2, are currently on trial for this type of cancer. Cetuximab Cetuximab, a chim Rer was seen anti-EGFR, anti-proliferative and pro apoptotic activity suspend t in pr Clinical models of HCC, but did not provide objective response rate in both studies. The time to progression was as low as 8 weeks in one study, although the authors of the second study, a median survival time of 9.6 months was pretty well what gt the need for further testing of this drug racket Eren and gr series. In another study, cetuximab, in combination with chemotherapy gemcitabine and oxaliplatin. This combination provided an answer of 23 goals, 65 embroidered with the disease, and a decrease